Four British Medical Journal
(BMJ) articles have challenged
Boehringer Ingelheim’s decision
to withhold significant data from
regulators around the safety of
Pradaxa (dabigatran) while it was
under review, reports Medscape.
The company, the reports allege,
kept private the conclusion of at
least some of its researchers that
monitoring-guided dabigatran
dosing “has the potential to provide
patients an even better efficacy
and safety profile than fixed-dose
dabigatran and also a better safety
and efficacy profile than a matched
warfarin group.”
CLICK HERE to read the
Medscape review.The above article was sent to subscribers in Pharmacy Daily's issue from 25 Jul 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 25 Jul 14
RESPONDING to the findings from the Royal Commission into Aged Care Quality and Safety, a recent government initiative aims to improve medication management in residential aged care facilities by introducing on-site pharmacists.
RESEARCHERS at Charles Darwin University (CDU) are advancing a novel drug delivery system that could potentially eliminate the need for injections to treat various chronic diseases.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.